glp-1 news october 1 2025 How FDA Crackdowns Are Affecting Use In What Patients Need to Know

Br J Haematol (2001) 115(1):1924

The FDA and EMA approvals of ZepBound in late 2023 and early 2024 (for weight management) were major regulatory milestones achieved by Lilly ahead of many competitors

Here is why: Glutathione inhibits tyrosinase the enzyme that triggers melanin production in response to UV radiation

Most large-scale trials have had relatively short follow-up periods (typically 2 to 4 years), and the sustained efficacy of these therapies beyond this timeframe has not been fully established

I think we built medical specialties based on the complications of obesity. When you look at cardiology, nephrology, neurology, many of the diseases they treat share overlapping drivers